HomeCompareFRTX vs GBDC

FRTX vs GBDC: Dividend Comparison 2026

FRTX yields 213.90% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRTX wins by $156.31M in total portfolio value
10 years
FRTX
FRTX
● Live price
213.90%
Share price
$0.94
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$177.09M
Annual income
$92,250,740.75
Full FRTX calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — FRTX vs GBDC

📍 FRTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRTXGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRTX + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRTX pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRTX
Annual income on $10K today (after 15% tax)
$18,181.82/yr
After 10yr DRIP, annual income (after tax)
$78,413,129.64/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, FRTX beats the other by $64,482,255.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRTX + GBDC for your $10,000?

FRTX: 50%GBDC: 50%
100% GBDC50/50100% FRTX
Portfolio after 10yr
$98.93M
Annual income
$54,320,002.07/yr
Blended yield
54.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

FRTX
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-18.7
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRTX buys
0
GBDC buys
0
No recent congressional trades found for FRTX or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRTXGBDC
Forward yield213.90%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$177.09M$20.78M
Annual income after 10y$92,250,740.75$16,389,263.41
Total dividends collected$167.49M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: FRTX vs GBDC ($10,000, DRIP)

YearFRTX PortfolioFRTX Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$32,090$21,390.37$12,490$1,790.28+$19.6KFRTX
2$98,489$64,151.88$16,522$3,157.73+$82.0KFRTX
3$289,391$184,008.00$23,578$5,898.68+$265.8KFRTX
4$814,951$505,302.85$37,115$11,886.75+$777.8KFRTX
5$2,201,885$1,329,887.07$66,136$26,423.57+$2.14MFRTX
6$5,714,120$3,358,103.33$137,257$66,491.44+$5.58MFRTX
7$14,258,620$8,144,511.98$341,734$194,868.54+$13.92MFRTX
8$34,250,418$18,993,694.31$1,050,788$685,133.02+$33.20MFRTX
9$79,287,637$42,639,690.06$4,099,314$2,974,971.01+$75.19MFRTX
10$177,088,513$92,250,740.75$20,775,530$16,389,263.41+$156.31MFRTX

FRTX vs GBDC: Complete Analysis 2026

FRTXStock

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Full FRTX Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this FRTX vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRTX vs SCHDFRTX vs JEPIFRTX vs OFRTX vs KOFRTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.